You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 197 Novel FcyR recombinant fusion facilitates antibody arming of engineered iPSC-derived NK cells to enhance targeting and killing of ovarian cancer cells

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Cellular Therapies
197 Novel FcyR recombinant fusion facilitates antibody arming of engineered iPSC-derived NK cells to enhance targeting and killing of ovarian cancer cells
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to March 2024

AbstractFullPdf
Nov 2021337040
Dec 202174016
Jan 202252023
Feb 202268019
Mar 2022386030
Apr 2022140021
May 202268017
Jun 202260025
Jul 20224407
Aug 20227804
Sep 202269016
Oct 20227408
Nov 202284012
Dec 20225406
Jan 202378017
Feb 20236606
Mar 20233807
Apr 202338015
May 20233407
Jun 20232608
Jul 20231409
Aug 2023605
Sep 20231601
Oct 20232405
Nov 20232002
Dec 20233802
Jan 20243602
Feb 20242603
Mar 20241405
Total20620338